Gady Cojocaru
Holon, TA, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation.
Journal: Experimental hematology
Published: July 24, 2024
PVRIG is Expressed on Stem-Like T Cells in Dendritic Cell-Rich Niches in Tumors and Its Blockade May Induce Immune Infiltration in Non-Inflamed Tumors.
Journal: Cancer immunology research
Published: September 12, 2023
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects.
Journal: Cancer immunology research
Published: August 28, 2023
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Journal: Journal for immunotherapy of cancer
Published: February 10, 2021
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Journal: Cancer immunology, immunotherapy : CII
Published: September 13, 2020
The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 23, 2019
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2).
Journal: Cancer immunology research
Published: May 08, 2019
ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 02, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026